**Core tip:** The prognosis of advanced hepatocellular carcinoma (HCC) has been improved in the last years due to new available drugs for first and second line systemic treatments. Recent improvements in HCC molecular mechanisms have led to development of effective systemic treatments including tyrosine kinase inhibitors and immunotherapy. In this review, we describe first and second line systemic treatment options for advanced HCC focusing on sequencing therapy and comparison of different second line options.

INTRODUCTION
============

Primary liver cancer or hepatocellular carcinoma (HCC) is the fifth most common neoplasm and the third leading cause of cancer related death worldwide\[[@B1]\]. Its prognosis in advanced stages has been improved in the last years because of new available drugs for first and second line systemic treatment options\[[@B2]\].

During the last decades, further knowledge of HCC molecular mechanisms has led to the development of effective systemic treatment including tyrosine kinase inhibitors (TKIs) and immunotherapy. In this review, we describe first and second line systemic treatment options for advanced HCC focusing on sequencing therapy (sorafenib-based treatment) and comparison of different second line options (Figure [1](#F1){ref-type="fig"}).

![First and second line therapies for advanced hepatocellular carcinoma. RECIST: Response Evaluation Criteria for Solid Tumors; ECOG: Eastern Cooperative Oncology Group; SOR: Sorafenib.](WJG-26-1888-g001){#F1}

FIRST LINE SYSTEMIC TREATMENT
=============================

Sorafenib was the first effective treatment approved for advanced HCC\[[@B3]\]. Two double-blind, randomized clinical trials (RCTs) demonstrated a better overall survival (OS) with a relative risk reduction of death of 70% \[HR (hazard ratio) of 0.69 \[95% confidence interval (CI): 0.55; 0.87)\] for sorafenib against placebo/best supportive care\[[@B3],[@B4]\]. Likewise, a benefit was observed in prolonging time to radiological progression (TTP), evaluated through Response Evaluation Criteria for Solid Tumors (RECIST 1.0)\[HR: 0.58 (95%CI: 0.45; 0.74)\]\[[@B5],[@B6]\]. In these trials, sorafenib could be continued even after radiological tumor progression, *i.e*., until symptomatic progression, intolerance or death. The median TTP under sorafenib was 5.5 mo. In the SHARP and Asia-Pacific trials, although there was a low objective response rate (ORR) (less than 2%), stable disease (SD) was observed in more than 70% with a disease control rate (DCR) of 43% and 53%, respectively\[[@B3],[@B4]\]. Thus, sorafenib reached its main primary end-point with a benefit in overall survival, even without significant tumor shrinkage. This phenomenon opened a paradigm in clinical oncology and trial design for systemic treatment for HCC.

Several observational cohort studies validated the use of sorafenib in the real life setting. The GIDEON study was an observational prospective cohort study whose primary objective was to evaluate the effectiveness of sorafenib in these scenarios, particularly in patients with advanced liver disease\[[@B7]\]. There was a higher incidence of adverse events (AEs) and treatment discontinuation due to AEs in patients with Child Pugh B-C when compared to Child Pugh A. Median survival was significantly lower in patients with unpreserved liver function. Other series from Italy and Argentina reported similar outcomes\[[@B8],[@B9]\].

Some authors still argue that systemic chemotherapy has a therapeutic role in these patients since sorafenib showed a low radiological response, a poor gain in survival, absence of predictive response factors and a high cost. However, over the past decades, trials or uncontrolled interventional studies with doxorubicin\[[@B10]-[@B13]\], cisplatin, oxaliplatin or FOLFOX, gemcitabine-based GEMOX\[[@B14]-[@B19]\], capecitabine-based XELOX\[[@B20]\] or in combination with bevacizumab\[[@B21]\], have all failed with no proven efficacy and eventually accompanied by high toxicity rates. Finally, recent trials exploring the efficacy of sorafenib in combination with arterial chemotherapy have shown contradictory results\[[@B22],[@B23]\].

Since 2008, different molecular pathways of HCC development and progression have been studied in depth. Based on these studies, many clinical trials were conducted testing new drugs for HCC first-line treatment. To date only lenvatinib has demonstrated to be non-inferior to sorafenib (Table [1](#T1){ref-type="table"}). Sunitinib, an endothelial growth factor inhibitor (EGFR), has failed to demonstrate non-inferiority in a phase III RCT\[[@B24]\]. There was a lot of expectation with brivanib (BRISK-FL trial) given its anti-angiogenic effect and different inhibition of pathways than sorafenib (vascular-endothelial growth factor -VEGF- and fibroblast growth factor--FGF-pathways). However, it was also not efficient in a non-inferiority trial\[[@B25]\]. Other phase III trials failed to show superiority, including: erlotinib + sorafenib *vs* sorafenib + placebo (SEARCH trial, anti EGFR)\[[@B26]\], linifanib *vs* sorafenib (VEGF and platelet-derived growth factor inhibitor-PDGF)\[[@B27]\]. Likewise, dovitinib (VEGF, FGF and PDGF inhibitor)\[[@B28]\] and bevacizumab (anti-VEGF monoclonal antibody) did not demonstrate efficacy in phase II trials, presenting excessive toxicity and high incidence of sepsis, not allowing for further studies\[[@B29]\].

###### 

First line agents failed for the treatment of advanced hepatocellular carcinoma

  **Study drug**                                             **Population**                                   **Design-intervention**                                                     **Results**
  ---------------------------------------------------------- ------------------------------------------------ --------------------------------------------------------------------------- ------------------------------------------------------------------------------
  Sunitinib (EGFR), Cheng et al\[[@B24]\], 2013              *n* = 1074, BCLC B-C, ECOG 0-1, Child Pugh A/B   RCT Fase III. Non-inferiority. Sunitinib *vs* Sorafenib                     Failed to reach its primary end-point. Higher rate of EAs
  Brivanib (VEGF, FGF), Johnson et al\[[@B25]\], 2013        *n* = 1150, BCLC B-C, ECOG 0-1, Child Pugh A/B   RCT Fase III. Non-inferiority. Brivanib *vs* Sorafenib (Bristol)            Failed to reach its primary end-point. Higher rate of EAs
  Erlotinib (EGFR), Zhu et al\[[@B14]\], 2006                *n* = 720, BCLC B-C, ECOG 0-1, Child Pugh A/B    RCT Fase III. Superiority, Erlotinib + Sorafenib *vs* Placebo + Sorafenib   OS similar, TTP similar, Similar EAs
  Linifanib (VEGF, PDGF), Cainap et al\[[@B27]\], 2015       *n* = 1035, BCLC B-C, ECOG 0-1, Child Pugh A/B   RCT Fase III. Superiority, Linifanib *vs* Sorafenib                         Failed to reach its primary end-point. TTP better for linifanib, Similar EAs
  Tigatuzumab, Bruix et al\[[@B30]\], 2017                   *n* = 162, BCLC B-C, ECOG 0-1, Child Pugh A/B    RCT Fase II, Tigatuzumab + Sorafenib *vs* Placebo + Soraf                   Safety profile adequate but no better TTP and OS
  Dovitinib (VEGF, FGF, PDGF), Cheng et al\[[@B28]\], 2016   *n* = 165, BCLC B-C, ECOG 0-1, Child Pugh A/B    RCT Fase II. Dovitinib *vs* Sorafenib                                       OS non superior, TTP similar, Higher rate of EAs
  Bevacizumab (Ab VEGF), Hubbard et al\[[@B29]\], 2016       *n* = 17, BCLC B-C, ECOG 0-1, Child Pugh A/B     RCT Fase I/II, Bevacizumab + Sorafenib                                      Higher rate of EAs, Excessive toxicity

BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group; EGFR: Endothelial growth factor; FGF: Fibroblast growth factor; OS: Overall survival; PDGF: Platelet-derived growth factor inhibitor; TTP: Time to progression; VEGF: Vascular-endothelial growth factor; RCT: Randomized clinical trials.

The only pre-treatment sorafenib predictors of better survival are the absence of extrahepatic disease, hepatitis C as an underlying disease and a low neu-trophil/leukocyte ratio\[[@B30]\]. High serum Alpha-fetoprotein (AFP) values (\> 200 ng/mL) and macroscopic vascular invasion are baseline variables associated with poor prognosis in these patients, but even in these subgroups, sorafenib showed a survival benefit *vs* placebo\[[@B30]\].

Results of a phase II and then a phase III RCT (REFLECT trial), have shown that lenvatinib, a VEGF receptors 1-3, FGF receptors 1-4 and PDGF α receptor inhibitor, was the first agent achieving non-inferiority against sorafenib\[[@B31],[@B32]\]. The eligibility criteria in the REFLECT study were different from SHARP and Asia-Pacific studies, *i.e*., excluding those patients with main portal trunk tumor invasion and those subjects with intrahepatic tumor involvement of more than 50% of total liver volume\[[@B32]\]. The REFLECT study was an open-labeled phase 3 RCT, in which the primary objective was non-inferiority survival with respect to sorafenib (upper HR confidence interval limit of 1.08)\[[@B32]\]. In the intention-to-treat analysis, patients with lenvatinib presented a median survival of 13.6 mo, whereas those in the sorafenib arm had a median survival of 12.3 mo (HR: 0.92, 95%CI: 0.79-1.06). Likewise, a better progression-free survival (PFS) and TTP were observed, together with a higher ORR for lenvatinib over sorafenib (Figure [2](#F2){ref-type="fig"}).

![Radiological tumor response between sorafenib and lenvatinib according to RECIST 1.1 criteria, reported in the REFLECT trial. RECIST: Response Evaluation Criteria for Solid Tumors; ORR: Objective response rate.](WJG-26-1888-g002){#F2}

Although this study demonstrated that lenvatinib is an effective first-line treatment option for advanced HCC, there are some important points to be considered. First, the non-inferiority design should have been characterized by less toxicity rates with lower discontinuation rates due to AEs as a co-primary end-point. However, these events were not included as co-primary end-points\[[@B32]\]. Second, the non-blinded design might have generated a possible intervention bias, justifying the longer treatment duration in lenvatinib arm (median treatment duration of 5.7 mo) compared to sorafenib arm (median treatment duration of 3.7 mo)\[[@B32]\]. Thus, if there was a similar tolerance between groups, this observation is striking and can only be explained by the design. Treatment duration with sorafenib was shorter, even when compared with previous RCT\[[@B3],[@B4]\] and there was not a significant difference regarding treatment discontinuation rates between both arms. Consequently, the effect upon survival might have been biased due to a premature sorafenib interruption. Indeed, a higher incidence of severe AEs were observed in the lenvatinib arm (57% *vs* 49%)\[[@B32]\]. Lenvatinib was characterized by a higher incidence of arterial hypertension, proteinuria, dysphonia and hypothyroidism, while diarrhea, hand-foot reaction and alopecia were more frequent with sorafenib. However, this is opposed to the fact that lenvatinib showed higher tumor shrinkage rates\[[@B32]\]. Moreover, the adoption of different second line drugs (that subsequently revealed to be effective) following sorafenib and lenvatinib, might have influenced the post-progression overall survival.

The REFLECT trial modifies the future therapeutic options in patients with advanced HCC. It remains unclear which subgroup of patients will benefit more with one drug or another, as well as what will be the drug of choice for second line after tumor progression with lenvatinib. Thus, the appropriate selection of each treatment should be individualized.

More recently, immunotherapy has evolved as a potential first line systemic option. From a previous phase Ib-II trial escalating-dose, nivolumab (3 mg/kg every 2 wk-schedule) showed promising tumor responses in sorafenib-experienced patients\[[@B33]\]. These results leaded to perform a phase III RCT, in which nivolumab was tested against sorafenib in the first-line setting (Check-Mate 459 study; NCT02576509). Unfortunately, results were negative for both co-primary end-points of OS \[16.4 mo (95%CI: 13.9-18.4) *vs* 14.7 mo (95%CI: 11.9-117.2), *P* = 0.0752\] and PFS \[3.7 mo (95%CI: 3.1-3.9) *vs* 3.8 mo (95%CI: 3.7-4.5)\].

These negative results have been recently counterbalanced by positive results of a phase III, open-label, randomized trial evaluating the combination of atezolizumab, another immune-checkpoint inhibitor, with bevacizumab, an anti-VEGF monoclonal antibody, compared to sorafenib. Eligibility criteria included preserved liver function, advanced HCC, ECOG 0-1 in the absence of main portal trunk invasion and immunological disorders. Both co-primary end-points, OS HR 0.58 (CI: 0.42-0.79) \[median survival not reached *vs* 13.2 mo with sorafenib alone, *P* = 0.0006\] and PFS HR 0.59 (CI: 0.47-0.76; *P* \< 0.0001) were longer for the new treatment combination (NCT03434379; IMbrave150 study). A significant higher ORR rate in the combination arm 27% *vs* 12% and DCR of 74% *vs* 55% (*P* \< 0.0001) were observed. Similar incidence of all grade adverse events and a lower incidence of grades 3/4 related adverse events were observed with the combination arm (36% *vs* 46%). The most frequent adverse events were systemic hypertension, diarrhea, proteinuria, hyporexia, elevated liver enzymes and infusional reaction. However, treatment discontinuation was higher in atezolizumab + bevacizumab arm (16% and 10%, respectively) These results opened a new and potentially unlimited therapeutic options and are currently being studied in several phase-3 trials.

SECOND LINE SYSTEMIC TREATMENT: WHEN AND TO WHOM?
=================================================

Three potential scenarios can develop during first line systemic treatment, which determine the subsequent patients' management: (1) Tolerance or intolerance; (2) Radiological progression; and (3) Symptomatic progression (Figure [3](#F3){ref-type="fig"}).

![Clinical "stopping rules" of first and second line tyrosine kinase inhibitors. RECIST: Response Evaluation Criteria for Solid Tumors; ECOG: Eastern Cooperative Oncology Group; RECIST: Response Evaluation Criteria for Solid Tumors criteria.](WJG-26-1888-g003){#F3}

Tolerance has been defined and applied as eligibility criteria in second line phase III RCTs after sorafenib treatment. In the RESORCE trial, tolerance was defined according to a specific time-dosing schedule as ≥ 400 mg during at least 20 d of the last 28 d under sorafenib\[[@B34]\]. In another trial, this definition was focused on the severity of adverse events, its complete resolution and no recurrence after reintroduction of sorafenib\[[@B35]\]. Consequently, tolerance or intolerance have been differently defined in RCT, focusing on the dosing-scheme or based on AEs severity. These clinical definitions are important to systematize the decision-making process in the daily practice.

The concept of radiological tumor progression has been focused during the last decade. As previously discussed, sorafenib granted an OS benefit even without tumor shrinkage\[[@B3],[@B4]\]. On the other hand, TTP has failed to be a surrogate marker of survival benefit in HCC. For this reason, the reliability of TTP as a survival predictor is questionable in HCC, eventually other measures like disease free survival should be taken into account. Several examples have been published showing a benefit in TTP without any significant improvement in OS\[[@B36],[@B37]\]. Thus, it seems that TTP does not accurately correlate with OS in advanced HCC. TTP might be exposed to several bias. Tumor progression can be evaluated by RECIST 1.1 or modified RECIST criteria for HCC (mRECIST)\[[@B38]\]. It should be noted that there might be some inconsistencies defining new lesions between both criteria. Moreover, RECIST 1.1 is more stringent than mRECIST when defining partial and complete responses and mRECIST could be more difficult to assess under heterogeneous tumor enhancement areas.

Radiological tumor defines eligibility for second-line treatment. However, radiological tumor progression can be distinguished in four different patterns with a different impact on OS\[[@B39],[@B40]\]. The key clinical question is when to move to second line treatment under tumor progression in a patient tolerating treatment or even more strikingly, if during treatment the patient has shown clinical benefit hallmarks such as dermatological events\[[@B41]\]. A new intrahepatic lesion has a better prognosis than a new extrahepatic lesion or a new vascular invasion\[[@B39],[@B40]\]. Therefore, second-line systemic treatment might be initiated under worst types of patterns of progression and may be delayed for a second progression in case of intrahepatic progression pattern.

Symptomatic progression is defined as progression beyond an ECOG PS 2\[[@B42]\]. Since most HCCs develop in patients with chronic liver disease, the conjunction of tolerability, treatment complications and risk of cirrhosis decompensation, make this cancer a huge therapeutic challenge. In the same patient, symptomatic progression might be due to cancer-related symptoms or those associated with liver disease decompensation. Therefore, in the same patient there may be "tumor radiological progression" or "untreatable progression" due to development of liver de-compensation as a competing event for OS\[[@B40]\].

Following systemic treatment, drug-related adverse events and complications due to liver disease should be evaluated at each visit, which will determine the need for dose reduction, transient or definitive suspension of the drug. These events define a patient as "intolerant" or "not a candidate" for second line treatment at all. This definition is important in the clinical practice since it defines not only who is potential candidate to start treatment with second-line drugs but also with which drug may be treated.

SECOND LINE COMPETITORS
=======================

Several clinical trials failed to show any benefit as 2^nd^ line treatment option for advanced HCC in terms of OS when compared to placebo until the RESORCE study\[[@B34]\]. Brivanib (BRISK-PS, phase III RCT)\[[@B36]\], axitinib (phase II study)\[[@B43]\], everolimus (EVOLVE-1 phase III RCT)\[[@B44]\] and tivantinib\[[@B45]\] have all failed to show a benefit in OS *vs* placebo (Table [2](#T2){ref-type="table"}). In particular, Tivantinib, a MET pathway inhibitor (hepatocyte growth factor blockade), had shown promising results in a phase II RCT\[[@B46]\]. However, a phase III study paradoxically turned negative, even in patients highly expressing MET mutation\[[@B45]\]. This RCT has shown the lack of utility of tumor biopsy as a predictor of the therapeutic response in HCC (c-MET), subsequently confirmed in the CHECKMATE 040 and KEYNOTE-240 studies with nivolumab and pem-brolizumab\[[@B33],[@B35]\], where the expression on PD-1 in tumor tissue failed to predict treatment response.

###### 

Second line tyrosine kinase inhibitors approved for the treatment of advanced hepatocellular carcinoma

  **Study drug**                                       **Population**                                                                                       **Design-intervention**                                 **Results**
  ---------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------------------- -----------------------------------------------------------
  Regorafenib, Bruix et al\[[@B34]\], 2017, resorce    *n* = 553, BCLC B-C, ECOG 0-1, Child Pugh A, SOR-Tolerant                                            RCT phase III. Superiority. Regorafenib *vs* placebo    OS HR 0.63 (CI: 0.50-0.79), ORR 11%, DCR 65% (mRECIST)
  Cabozantinib, Abou-Alfa et al\[[@B47]\], Celestial   *n* = 707, BCLC B-C, ECOG 0-1, Child Pugh A, 1-2 prior systemic treatment, SOR-Tolerant/intolerant   RCT phase III. Superiority. Cabozantinib *vs* placebo   OS HR 0.76 (CI: 0.63-0.93), ORR 4%, DCR 64% (RECIST 1.1)
  Ramucirumab, Zhu et al\[[@B48]\], reach I-II         *n* = 542, BCLC B-C, ECOG 0-1, Child Pugh A, AFP ≥ 400 ng/mL, SOR-Tolerant/intolerant                RCT phase III. Superiority. Ramucirumab *vs* placebo    OS HR 0.69 (CI: 0.57-0.84), ORR 5%, DCR 60%, (RECIST 1.1)

Comparison across studies should cautiously analyzed. BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group; OS: Overall survival; HR: Hazard ratio; SOR: Sorafenib; ORR: Objective response rate; RCT: Randomized clinical trials; DCR: Disease control rate; AFP: Alpha-fetoprotein.

Currently, regorafenib\[[@B34]\], cabozantinib (CELESTIAL phase III RCT)\[[@B47]\] and ramucirumab (REACH I and REACH II phase III RCTs)\[[@B48]\] have demonstrated second-line efficacy. A controversial issue has raised with pembrolizumab regarding statistical and clinical results of the KEYNOTE-224 RCT. Although the trial was negative according to its pre-established primary efficacy end-points, it showed a survival benefit that promoted its acceptance as a new second line systemic option\[[@B35]\]. On the other hand, nivolumab can be used as a second line option--at least in United States, following positive results of the uncontrolled phase I/II CHECK MATE 040 trial\[[@B33]\].

ANTI-TYROSIN KINASE INHIBITORS FOR SECOND LINE THERAPY
======================================================

Both sorafenib and regorafenib are TKIs, but regorafenib is more active on VEGF, produces more intense inhibition on c-KIT receptor and partially blocks the TIE2 receptor\[[@B49]\]. The RESORCE phase III RCT included patients with advanced HCC who were tolerant and progressed under treatment with sorafenib\[[@B34]\]. The randomization was stratified 2:1 according to AFP values \> 400 ng/mL, presence of macrovascular invasion, extrahepatic spread and ECOG 0-1. The median OS was 10.6 mo (CI: 9.1; 12.1) for regorafenib and 7.8 mo (CI 6.3; 8.8) for placebo, with a HR of 0.62 (95%CI: 0.50-0.79)\[[@B34]\]. Likewise, regorafenib presented a benefit over TTP, with an ORR of 11% and a DCR of 65%; evaluated through both RECIST 1.1 and mRECIST. In post-hoc analyzes, regorafenib presented an OS benefit in all clinical scenarios including patients with baseline worst prognosis\[[@B34]\]. Overall, 93% of the patients receiving regorafenib presented AEs (*i.e*., high blood pressure, fatigue, diarrhea and hand--foot reaction), 46% grade III and 4% grade IV, with drug discontinuation due to intolerance in 10% of the patients\[[@B34]\] (Table [3](#T3){ref-type="table"}).

###### 

Scheme dose, adverse events and discontinuation rate of first and second line tyrosine kinase inhibitors and anti-vascular-endothelial growth factor agents approved for the treatment of advanced hepatocellular carcinoma

  **Study drug**   **Dose reduction - interruption**                                                                                                                      **Discontinuation rate**
  ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------
  Sorafenib        26% dose reduction (any AE), 44% drug interruption (any AE), most frequent AE leading to dose reductions: diarrhea, hand-foot skin reaction and rash   11%
  Lenvatinib       37% dose reduction (related-AE), 40% drug interruption (related-AE), Most frequent AE leading to dose reductions: not reported                         9%
  Regorafenib      68% dose reduction or drug interruption (any AE), most frequent AE leading to dose reductions: diarrhea, hand-foot skin reaction                       10%
  Cabozantinib     62% dose reduction or drug interruption (any AE), most frequent AE leading to dose reductions: diarrhea, hand-foot skin reaction                       16%
  Ramucirumab      34% dose reduction or drug interruption (any AE), most frequent AE leading to dose reductions: fatigue, peripheral edema, hypertension and anorexia    11%

Comparison across studies should cautiously analyzed. AE: Adverse event.

Cabozantinib has been recently approved by both EMA and FDA as another second line treatment option. The phase III CELESTIAL RCT of cabozantinib 60 mg/d showed positive results *vs* placebo for OS \[HR: 0.76 (CI: 0.63; 0.93); *P* = 0.005\] and disease free survival \[HR: 0.44 (CI: 0.36; 0.52)\]\[[@B47]\]. Cabozantinib, initially considered a dual VEGFR-2 and c-MET inhibitor, subsequently showed activity on MET, AXL, RET, FLT3 and Tie-2 pathways\[[@B50]\]. The CELESTIAL study included patients with advanced HCC, Child Pugh A, ECOG PS 0-1, with up to two previous systemic treatments, including sorafenib prior exposure, independently from tolerance. Patients were stratified according to etiology of liver disease (HBV or HCV), presence of macrovascular invasion, extrahepatic spread and world region and were randomized 2:1. The OS was 10.2 mo (CI: 9.1-12.0) for cabozantinib and 8 mo (CI: 6.8-9.4) for placebo. Cabozantinib presented lower TTP, with an ORR of 4%, SD of 60% and a DCR of 64%\[[@B47]\]. Dose reductions and discontinuations were more common in the cabozantinib arm, as were AEs (Table [3](#T3){ref-type="table"}). No data have been reported in the post-hoc analysis regarding the effect of cabozantinib according to sorafenib tolerance, while cabozaninib showed higher survival than placebo with a median survival of 11.3 mo *vs* 7.2 mo \[HR: 0.74 (CI: 0.59-0.92\] among patients receiving sorafenib as the single prior systemic therapy\[[@B47]\].

OTHER ANTIANGIOGENIC AGENTS FOR SECOND LINE THERAPY
===================================================

Prior studies have shown that AFP values are associated with worst OS in patients with advanced HCC and correlate with VEGF pathways, a critical role in angiogenesis. The anti-VEGF monoclonal antibody, ramucirumab, has been initially tested in second line treatment (whether sorafenib tolerant or not) in two phase III RCTs\[[@B48],[@B51]\]. In the REACH I study, there was not a significant difference in OS\[[@B51]\]. However, from a post hoc analysis, ramucirumab showed better OS when compared to placebo in patients with AFP values equal or higher than 400 ng/mL\[[@B51]\]. This led to the design of the REACH II trial, which included patients with advanced HCC with AFP values ≥ 400 ng/mL who were intolerant or progressed under sorafenib\[[@B48]\]. This study confirmed that ramucirumab reduced the risk of death by 29%, with a median OS of 8.5 mo *vs* 7.3 mo for the placebo group \[HR of 0.71 (95%CI: 0.53-0.95)\]. Moreover, a better TTP was observed with an ORR and DCR of 5% and 60%, respectively. Ramucirumab was associated with a higher incidence of AEs, mainly hyponatremia and arterial hypertension (Table [3](#T3){ref-type="table"}). This study was the first one showing efficacy based on a specific biomarker.

IMMUNOTHERAPY IN SECOND LINE THERAPY
====================================

Immunotherapy in HCC has been initially explored as second line options in patients with post-sorafenib tumor progression (tolerant or intolerant). Tremelimumab (anti-CTLA4) has been explored in an uncontrolled phase II exploratory trial in HCV+ patients following at least one prior systemic treatment\[[@B52]\]. The CheckMate 040 study, a phase I/II uncontrolled trial, evaluated nivolumab (anti PD-1) dose expansion and escalation scheme in patients with advanced HCC, Child Pugh A or B\[[@B33]\]. There was a promising ORR of 20%, with 3 complete responses (CR) and a DCR of 64%. The 9-mo survival rate was 74% (CI: 67%-79%). Baseline tumor levels of PD-L1 expression did not impact overall responses. The most common adverse effects observed were rash, elevation of liver and pancreatic enzymes and pruritus. Immunological adverse events were reported in less than 10% of the patients. This led to its temporary approval by the FDA in the United States as a second-line treatment option.

Finally, the KEYNOTE-224 (NCT02702401) phase III RCT compared the anti-PD1 pembrolizumab *vs* placebo for patients with advanced HCC, with tumor progression or intolerant to prior treatment with sorafenib\[[@B35]\]. Included patients had advanced HCC without main portal trunk tumor invasion, ECOG PS 0-1 and preserved liver function and were stratified according to baseline AFP values \> 200 ng/mL, ECOG 0-1 and world region. The trial did not meet its primary efficacy end-points (OS and PFS). However, median OS was longer for pembrolizumab (13.9 mo) *vs* placebo (10.6 mo) with a HR of 0.78 (CI: 0.61-0.99); *P* = 0.024. The upper limit of the CI almost crossed the line of no effect as proposed by the null hypothesis with an expected statistical significance of *P* = 0.017. Thus, this was the reason for this negative trial, although there was a higher ORR (18.8% *vs* 4.4%) and DCR (62% *vs* 53%). Most common treatment-related AEs were pruritus in 13%, fatigue 10%, increased liver function tests 9%, diarrhea 8% and rash 8%. Immune-mediated adverse events were reported in 18% of the patients with pembrolizumab, 7.2% being grade 3 or 4. However, OS was longer in pembrolizumab arm *vs* placebo when survival was adjusted for subsequent anticancer therapies (13.9 *vs* 9.3 mo; HR: 0.67; CI: 0.48-0.92; *P* = 0.0066) or a two-stage survival analysis model (10.6 *vs* 7.6 mo; HR: 0.68; CI: 0.53-0.86; *P* = 0.0011).

FIRST AND SECOND LINE SEQUENTIAL TREATMENT
==========================================

A post-hoc retrospective analysis of the RESORCE trial evaluated the effect on survival of the sequential treatment of first and second line treatment with sorafenib-regorafenib: The sequential treatment granted 26 mo of median overall survival compared to 19.2 mo for the patients treated by sorafenib and placebo thereafter\[[@B53]\]. Sixty percent of the study population had a prior last sorafenib dose of 800 mg/d. Regorafenib was effective regardless the last treatment dose of sorafenib (full dose *vs* lower dose) but patients with lower doses of sorafenib presented higher rates of hand-foot skin reaction, fatigue and anorexia when compared to placebo. Thus, caution should be taken when treating patients who were tolerant to lower doses of sorafenib after initiation of regorafenib.

Other data regarding sequential treatment of sorafenib-other TKIs are lacking, however data on sequential use of lenvatinib and sorafenib will be soon available by the post-hoc analysis of the REFLECT trial in those patients treated with sorafenib after lenvatinib discontinuation (Figure [4](#F4){ref-type="fig"}).

![Flow chart for clinical-decision making processes of first and second line systemic treatment for advanced hepatocellular carcinoma. BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group.](WJG-26-1888-g004){#F4}

SEQUENTIAL SYSTEMIC TREATMENT IN SPECIAL POPULATIONS
====================================================

A special population excluded from RCT are patients with recurrent HCC following liver transplantation. The effect of sorafenib was reported in retrospective cohort studies with similar outcomes regarding survival and tolerability\[[@B54]\]. More recently, a retrospective cohort study including 28 patients evaluated the sequential therapy of sorafenib-regorafenib in this setting\[[@B55]\]. During regorafenib all patients had at least one adverse event, the most common grade 3/4 adverse events were fatigue and hand-foot skin reaction. Interaction between CYP3A4 metabolism was reported with higher plasma levels of immunosuppressive drugs increased. Median OS from regorafenib initiation was 12.9 (CI: 6.7-19.1 mo) and 38.4 mo (CI: 18.5-58.4 mo) from sorafenib initiation.

CONCLUSION
==========

Atezolizumab plus bevacizumab may be the future standard of care over in first-line. However, some patients may be still be treated with with sorafenib or lenvatinib, particularly those patients with immunotherapy contraindication or main portal trunk invasion (not for lenvatinib). Both are equivalent, except for the orphan-based evidence of sequential post-lenvatinib treatment for second line. Sorafenib-regorafenib sequencing therapy has opened a new paradigm with a life expectancy exceeding two years at least for those patients tolerant for sorafenib. This data being previously unthinkable 10 years ago. Other therapeutic options for second line treatment include cabozantinib (for both sorafenib-tolerant and intolerant patients) and ramucirumab (only for patients with AFP values ≥ 400 ng/mL). While some regulatory agencies have approved the use of immunotherapy even after failing trials (*i.e*., nivolumab and pembrolizumab), the identification of patients who could benefit from one or another option is still unclear. Other trials, either in first and second lines are being tested, with combination of immunotherapy plus TKIs, showing positive preliminary results. Further predictive biomarkers of treatment response are needed in order to better select patients for each specific treatment.
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